![Patrick van Berkel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Patrick van Berkel currently works at ADC Therapeutics SA, as Chief Scientific Officer.
Dr. van Berkel also formerly worked at Genmab A, as VP-Antibody, Technology & Chemistry from 2003 to 2012.
Dr. van Berkel received his doctorate degree in 1998 from the University of Leiden and undergraduate degree in 1991 from Radboud University Nijmegen.
Eerdere bekende functies van Patrick van Berkel
| Bedrijven | Functie | Einde |
|---|---|---|
| ADC THERAPEUTICS SA | Hoofd Techniek/Wetenschap/O&O | 01-03-2026 |
| GENMAB A/S | Hoofd Techniek/Wetenschap/O&O | 01-01-2012 |
Opleiding van Patrick van Berkel
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
66
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Genmab A/S
 Genmab A/S BiotechnologyHealth Technology Operates as a biotechnology company for improving the lives of people with cancer and serious diseases through antibody medicines | Health Technology |
University of Leiden
 University of Leiden Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Radboud University Nijmegen
 Radboud University Nijmegen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ADC Therapeutics SA
 ADC Therapeutics SA Pharmaceuticals: MajorHealth Technology Develops proprietary antibody drug conjugates for the treatment of both solid and hematological cancers | Health Technology |
